Sermorelin
Sermorelin
Also known as: Geref, GRF 1-29, Sermorelin Acetate
Overview
Key Facts
Primary Goal: A 29-amino acid GHRH analog representing the shortest fully functional fragment of native GHRH
A 29-amino acid GHRH analog representing the shortest fully functional fragment of native GHRH. It was previously FDA-approved for diagnosing and treating GH deficiency in children before being discontinued for commercial reasons. Half-Life 10-20 minutes Typical Dose 200–500 mcg Frequency once daily before bed Cycle Length 3-6 months
Dosing Information
Half-Life
10-20 minutes
Typical Dose
200–500 mcg
Frequency
once daily before bed
Cycle Length
3-6 months
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Sermorelin was FDA-approved in 1997 under the brand name Geref for pediatric GH deficiency diagnosis and treatment. Clinical trials demonstrated its ability to restore physiologic GH secretion patterns. It was voluntarily withdrawn from market in 2008 for commercial reasons, not safety concerns, and remains available through compounding pharmacies.
Frequently Asked Questions
Common questions about Sermorelin
UK-Specific Information
Exclusive data points and guidance for UK residents using Sermorelin
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.